Pei Zhang, Shi-Jun Yan, Jian Hu, Hai-Peng Liu, Wei Xia, Meng Yang, Qian-Huining Kuang, Kai-Li Shi, Meng-Zhen Fu, Chun-Lin Gao, Zheng-Kun Xia
Journal of investigative medicine : the official publication of the American Federation for Clinical Research 2024 AugThe aim of this study was to evaluate the clinical features, pathological characteristics, and prognosis in myeloperoxidase (MPO)-antineutrophil cytoplasmic antibodies (ANCA)-associated glomerulonephritis (AAGN) with renal arteritis. The study involved 97 children from five pediatric clinical centers with MPO-AAGN who exhibited distinct clinical features. The patients were divided into AAGN-A+ and AAGN-A-, based on the presence or absence of arteritis, and the disparities in clinical, histopathological characteristics, and prognosis between the two groups was evaluated. In contrast to the AAGN-A- group, the children in the AAGN-A+ group exhibited more pronounced clinical symptoms and renal pathological injury. Arteritis positively moderately correlated with the serum creatinine, interleukin-6, urinary neutrophil gelatinase-associated lipocalin, negatively moderately correlated with serum complement C3. The renal survival rate in the AAGN-A+ group was significantly poorer than AAGN-A- group (χ2 = 4.278, p = 0.039). Arteritis showed a good predictive value for end-stage kidney disease (ESKD), and C3 deposition, ANCA renal risk score and arteritis were independent risk factors for the development of ESKD in children with MPO-AAGN. Arteritis is a significant pathological change observed in children with MPO-AAGN, and the formation of arteritis may be related to the inflammatory response and activation of the complement system.
Pei Zhang, Shi-Jun Yan, Jian Hu, Hai-Peng Liu, Wei Xia, Meng Yang, Qian-Huining Kuang, Kai-Li Shi, Meng-Zhen Fu, Chun-Lin Gao, Zheng-Kun Xia. Clinical outcomes and clinico-pathological correlations in children with MPO-ANCA-associated glomerulonephritis showing renal arteritis. Journal of investigative medicine : the official publication of the American Federation for Clinical Research. 2024 Aug;72(6):511-521
PMID: 38594222
View Full Text